WellPoint Expects $20 Bil. Sales Growth By 2016 Through ACA’s Expanded Coverage
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Joe Swedish predicted that “enrollment growth in Medicaid, exchanges and other products could drive our annual run rate operating revenue to around $90 billion by 2016,” adding about $20 billion.
You may also be interested in...
Express Scripts Purchase Deal For NextRx Includes 10-Year PBM Contract With WellPoint
With the acquisition of the largest plan-owned pharmacy benefit manager, Express Scripts will move to second place among the big stand-alone PBMs, ahead of CVS Caremark.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.